Breaking News on Contract Research, Manufacturing & Clinical Trials

Big Sponsors > GlaxoSmithKline

Exova adds 3-years to GSK environmental monitoring contract

16-Jan-2017 - GSK has renewed an environmental monitoring contract with Exova across manufacturing sites in the UK and Ireland.

Pharma Consortium to investigate new drug development technique

04-Apr-2016 - The new consortium will evaluate cryo-electron microscopy’s potential for drug development.

Pierre Fabre deploys biosensors to enrich clinical trial data

17-Nov-2015 - Researchers at Pierre Fabre have started to use implantable chips as biosensors to improve the data gathered whilst monitoring clinical trial subjects.

Catalent: Suspension at French plant likely due to human interference

17-Nov-2015 - Out-of-place softgel capsules have led to the suspension of manufacturing at a site in France, and Catalent says the problem is almost certainly due to malicious actions.

CPhI Worldwide 2015

Rush to acquire ex-pharma sites means survival of the biggest for CMOs

22-Oct-2015 - As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say...

GSK keeps focus on core offerings with Romanian distribution divestiture

16-Oct-2015 - GSK has inked a deal to offload its Romanian subsidiary Europharma Distribution, saying distribution is not one of the Big Pharma’s core offerings.

Bavarian Nordic wins up to $33m to develop J&J Ebola vaccine

16-Sep-2015 - Danish biotech Bavarian Nordic has signed a $9m contract from Johnson & Johnson to improve stability of their joint Ebola vaccine. After options and milestone awards, payment could total $33m.

GSK backtracks on Memphis divestment plans, invests $2m

25-Aug-2015 - A GSK facility in Memphis Tennessee which was scheduled to be sold off will now receive $2m to improve its manufacturing infrastructure.


Parexel to lay off up to 125 transferred GSK employees

03-Aug-2015 - Beginning Sept. 30, Massachusetts-based CRO (contract research organization) Parexel will lay off as many as 125 of the 450 employees it brought on from GlaxoSmithKline (GSK) in North Carolina late last...

Environmental group welcomes DSM-Sinochem and GSK efforts to halt spread of antibiotic resistance

13-Jul-2015 - Antibiotic API makers have an obligation to ensure their activities do not spread resistance says a group that welcomed DSM-Sinochem’s commitment to environmentally-friendly production.

GSK back in China via new API manufacturing agreement with Desano

06-Jul-2015 - GSK’s HIV unit ViiV Healthcare and China-based Desano Pharmaceuticals have forged an agreement whereby Desano will manufacture the API of GSK’s HIV drug Tivicay (dolutegravir) in China.

Veeva: eTMF software makes CROs stand out from the cloud

02-Jun-2015 - Veeva Systems’ cloud-based software could be a decisive factor for pharma firms looking to select a CRO, the firm says as it reports a robust Q1.

Inhalable biologics: Serendex formulates with Novozymes’ Recombumin

20-May-2015 - Serendex Pharmaceutical is a step closer to developing an inhalable biopharmaceutical for lung disease after adopting stabilising tech from Novozymes.

GSK, UNC-Chapel Hill partner to accelerate search for HIV cure

11-May-2015 - The University of North Carolina at Chapel Hill and GlaxoSmithKline (GSK) are creating a new HIV research center and a jointly owned new company that will focus on discovering a...

Parexel sees modest quarterly growth as backlog rises by nearly $1bn

01-May-2015 - Although Parexel’s consolidated service revenue increased by only 2% for the quarter, the company reported that its backlog included gross new business wins of $942.4m, which was 5.3% higher than...

Russia sees slight dip in clinical trial approvals in Q1 2015

15-Apr-2015 - The Ministry of Health of the Russian Federation approved 151 total clinical studies in Q1 of 2015, which is 11% less than the same quarter last year, though by comparison,...

Quintiles, Parexel, PPD lead all CROs in US trial totals, review finds

14-Apr-2015 - CROs (contract research organizations) continue to collaborate with sponsors on more clinical trials in the US, though the largest companies, such as Quintiles, Parexel and PPD, are working on a...


TransCelerate launches two new initiatives to accelerate clinical trials

10-Apr-2015 - Industry group TransCelerate BioPharma has established two new global initiatives around placebo and standard of care data sharing, and electronic labels for clinical trials – both of which aim to...

GSK, Cold Spring Harbor Laboratory to develop obesity, Type 2 diabetes treatment

23-Mar-2015 - Cold Spring Harbor Laboratory (CSHL) will collaborate with GlaxoSmithKline to develop treatments for obesity and Type 2 diabetes. 

Exclusive interview

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

05-Mar-2015 - Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told the preclinical CRO may add scale to US...

Exclusive interview

It's not the size... CRO Simbec-Orion on why it can compete with Quintiles

05-Feb-2015 - Being a drug developer not just a service provider differentiates Simbec-Orion from the Big CROs according to CEO Ronald Openshaw, whose firm signed two strategic partnerships last week.

Parexel sees book-to-bill bounce back as GSK strategic partnership renewal bears fruit

30-Jan-2015 - One quarter after announcing a disappointing book-to-bill ratio, CRO Parexel has now renewed its strategic partnership with GlaxoSmithKline and seen its book-to-bill ratio jump to its highest level since 2012.

Parexel strong book-to-bill 'reassuring' for CRO demand, says analyst

13-Jan-2015 - Parexel’s improved book-to-bill ratio is a reassuring sign for the company and the CRO industry as a whole, according to a William Blair analyst.

Parexel set for more Big Pharma business in 2015, even if Pfizer names 3rd CRO

06-Jan-2015 - Parexel will see more business from its Big Pharma clients in 2015, even if Pfizer names a third CRO say analysts.

Medidata widening the gap on trial data competitors, say analysts

10-Dec-2014 - R&D investment and an integrated platform are widening the divide between Medidata and its competitors, according to analysts who are confident the trial data firm can achieve target sales of...

Key Industry Events


Access all events listing

Our events, Shows & Conferences...